Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale
Date
2025
Authors
Badrising, U.A.
Henderson, R.
Reddel, S.
Corbett, A.
Liang, C.
Reardon, K.
Ghaoui, R.
Bulsara, M.
Brady, S.
Brusch, A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Clinical and Experimental Rheumatology, 2025; 43(2):316-325
Statement of Responsibility
U.A. Badrising, R. Henderson, S. Reddel, A. Corbett, C. Liang, K. Reardon, R. Ghaoui, M. Bulsara, S. Brady, A. Brusch, D. Chan, J.D. Coudert, T. Fairchild, G. Jain, M.C. Kiernan, D. Leonard, T. Lloyd, J. Schmidt, M.P. McDermott, L. Sanders, C. Lowe, A.J. van der Kooi, C. Weihl, P. Mohassel, M. Simpson, A. Carroll, I. Cooper, K. Beer, K. Hiscock, S. Walters, A. Panicker, A. Doverty, A.J. Heim, M. van Heur-Neuman, O. Benveniste, M.M. Dimachkie, M. Needham
Conference Name
Abstract
OBJECTIVES: Inclusion body myositis (IBM) is a complex inflammatory muscle disease in adults over 40, with histological features of autoinflammation, cell stress and autophagic abnormalities, and marked clinically by relentless progression with no effective disease-modifying therapy. Sirolimus (rapamycin) may help maintain function by inhibiting T effector cells, preserving T regulatory cells, inducing autophagy, and improving mitochondrial function. This international trial follows a phase II pilot study. METHODS: This phase IIb/III double-blind, randomised, controlled trial (RCT) of sirolimus involves 140 IBM patients randomly assigned with equal allocation to sirolimus (2 mg) or matching placebo. This RCT aims to assess the efficacy of sirolimus compared to placebo in slowing or stabilising IBM progression, as measured by the mean change in patient function using the IBM Functional Rating Scale (IBM-FRS) from Baseline to Week 84. Secondary outcomes will evaluate efficacy and safety to inform future clinical trial design. RESULTS: Ethical approval has been granted in Australia (St Vincent’s Hospital Melbourne HREC-D 311/20) and the USA (University of Kansas Medical Center Human Research Protection Program FWA no. 00003411), with European approval pending. The protocol is version 3.0 (02-Dec-2022). Trial registration: ANZCTR: ACTRN12620001226998p, ClinicalTrials.gov: NCT04789070, UTN: U1111-1258-1354, and EU CT 2024-514575-17-00. CONCLUSIONS: This phase IIb/III trial builds on prior findings to assess sirolimus’s potential in slowing or halting IBM progression, preserving patient function and independence, and advancing IBM therapeutic strategies and trial design.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© Copyright Clinical and Experimental Rheumatology 2025.